Open Philanthropy recommended a grant of $195,000 to the Fred Hutchinson Cancer Center to support research investigating a potential way to make CAR T-cell therapy safer for cancer patients. The research, led by Alexandre V. Hirayama, will study whether an antibody (anti-Syndecan 2) can reduce dangerous side effects of CAR T-cell therapy while maintaining its effectiveness against cancer.
This falls within Open Philanthropy’s focus area of scientific research.